Eva V Vodegel, Sandra E Zwolsman, Astrid Vollebregt, Ruben G Duijnhoven, Judith E Bosmans, Leonie Speksnijder, Eveline J Roos, Wilbert Spaans, Franca Gerards, Albert Adriaanse, Flora Vernooij, Alfredo L Milani, Marko Sikkema, Mirjam Weemhoff, Marieke Mous, Anne Damoiseaux, Heleen van Dongen, Marinus V/D Ploeg, Joggem Veen, Geerte van de Pol, Bart Broekman, Pieternel Steures, Fernando Tjin-Asjoe, Jolande van der Stege, Ronald Mouw, Carl H van der Vaart, Jan-Paul W R Roovers
BACKGROUND: Surgery for pelvic organ prolapse (POP) is associated with high recurrence rates. The costs associated with the treatment of recurrent POP are huge, and the burden from women who encounter recurrent POP, negatively impacts their quality of life. Estrogen therapy might improve surgical outcome for POP due to its potential beneficial effects. It is thought that vaginal estrogen therapy improves healing and long-term maintenance of connective tissue integrity. Hence, this study aims to evaluate the cost-effectiveness of perioperative vaginal estrogen therapy in postmenopausal women undergoing POP surgery...
December 31, 2021: BMC Women's Health